RVNC - Revance Positive Data And Other News: The Good Bad And Ugly Of Biopharma
Revance Therapeutics Reports Positive Results from Facial Skin Trial
Revance Therapeutics (RVNC) reported positive data from its two Phase 2a clinical trials. Both the trials indicated that DaxibotulinumtoxinA or DAXI is efficacious as well as well tolerated. The first study sought to evaluate the drug candidate for treating dynamic forehead line following glabellar line injections while the second trial focused on the impact of the drug candidate on lateral canthal lines.
These two Phase 2a studies are open label, dose escalation trials. The studies involved multiple doses but were not powered to provide